Journal of Affective Disorders
Volume 87, Issue 1 , Pages 115-119 , July 2005

Is treatment-associated hypomania rare with duloxetine: Secondary analysis of controlled trials in non-bipolar depression

  • David L. Dunner

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, University of Washington Center for Anxiety and Depression, 4225 Roosevelt Way NE, Ste 306C, Seattle, WA 98105, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 206 543 6768; fax: +1 206 543 7565.
    • ,
  • Deborah N. D'Souza

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, United States
    • ,
  • Daniel K. Kajdasz

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, United States
    • ,
  • Michael J. Detke

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, United States
    • ,
  • James M. Russell

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, United States

Received 13 July 2004 ,Accepted 7 February 2005.

References 

  1. Akiskal HS, Bourgeois ML, Angst J, Post R, Moller H, Hirschfeld R. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J. Affect. Disord. 2000;59(Suppl. 1):S5–S30
  2. Amsterdam JD, Garcia-Espana F. Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J. Affect. Disord. 2000;59(3):225–229
  3. Amsterdam JD, Garcia-Espana F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J. Clin. Psychopharmacol. 1998;18(6):435–440
  4. Angst J. Switch from depression to mania—a record study over decades between 1920 and 1982. Psychopathology. 1985;18(2–3):140–154
  5. Benazzi F. Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. J. Affect. Disord. 1997;46(1):73–77
  6. Benazzi F, Akiskal HS. Delineating bipolar II mixed states in the Ravenna–San Diego collaborative study: the relative prevalence and diagnostic significance of hypomanic features during major depressive episodes. J. Affect. Disord. 2001;67(1–3):115–122
  7. Benazzi F, Akiskal HS. Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania. J. Affect. Disord. 2003;73(1–2):33–38
  8. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001;25(6):871–880
  9. Chun BJ, Dunner DL. A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V. Bipolar Disord. 2004;6(1):32–42
  10. Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int. Clin. Psychopharmacol. 1995;10(Suppl. 2):15–20
  11. De Montigny C, Silverstone PH, Debonnel G, Blier P, Bakish D. Venlafaxine in treatment-resistant major depressin: a Canadian multicenter, open-label trial. J. Clin. Psychopharmacol. 1999;19(5):401–406
  12. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J. Clin. Psychiatry. 2002;63(4):308–315
  13. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J. Psychiatr. Res. 2002;36(6):383–390
  14. Dunner DL, Hendrickson HE, Bea C, Budech CB. Venlafaxine in dysthymic disorder. J. Clin. Psychiatry. 1997;58(12):528–531
  15. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J. Clin. Psychiatry. 2000;61(10):804–808(Quiz 809)
  16. Henry C, Sorbara F, Lacoste J, Gindre C, Leboyer M. Antidepressant-induced mania in bipolar patients: identification of risk factors. J. Clin. Psychiatry. 2001;62(4):249–255
  17. Hirschfeld RM. Bipolar spectrum disorder: improving its recognition and diagnosis. J. Clin. Psychiatry. 2001;62(Suppl. 14):5–9
  18. Howland RH. Induction of mania with serotonin reuptake inhibitors. J. Clin. Psychopharmacol. 1996;16(6):425–427
  19. Kupfer DJ, Carpenter LL, Frank E. Possible role of antidepressants in precipitating mania and hypomania in recurrent depression. Am. J. Psychiatry. 1988;145(7):804–808
  20. Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt CH, Lu Y, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol. Bull. 2002;36(4):106–132
  21. Nielsen BM, Behnke K, Arup P, Christiansen PE, Geisler A, Ipsen E, et al. A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder. Acta Psychiatr. Scand. 1993;87(4):269–272
  22. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br. J. Psychiatry. 1994;164(4):549–550
  23. Physician's Desk Reference . Physician's Desk Reference. Montvale, NJ: Medical Economics Company Inc.; 2002;
  24. Rabkin JG, Quitkin FM, McGrath P, Harrison W, Tricamo E. Adverse reactions to monoamine oxidase inhibitors: Part II. Treatment correlates and clinical management. J. Clin. Psychopharmacol. 1985;5(1):2–9
  25. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry. 1998;59(Suppl. 20):22–33
  26. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 1997;340(2–3):249–258
  27. Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of anti-depressants—potential for greater efficacy or just hype?. Prog. Drug Res. 2002;58:169–222

PII: S0165-0327(05)00074-1

doi: 10.1016/j.jad.2005.02.017

Journal of Affective Disorders
Volume 87, Issue 1 , Pages 115-119 , July 2005

Article Tools